Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 3/20 | 0.51 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30732561 | 1.00 | GLS (0.51) | GLSKDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL12908113 | 0.90 | MMP13 (0.46) | GLSKDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL15805853 | 0.86 | NQO2 (0.51) | GLSNAMPTCA1CYP3A4IDO1 | |
| SCHEMBL1830157 | 0.85 | GLS (0.54) | GLSKDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL16099783 | 0.85 | GLS (0.42) | GLSBRD4CREBBPHDAC1CA12 | |
| SCHEMBL18805056 | 0.85 | GLS (0.42) | GLSBRD4CREBBPHDAC1CA12 | |
| SCHEMBL16089568 | 0.85 | GLS (0.42) | GLSBRD4CREBBPHDAC1CA12 | |
| SCHEMBL9118033 | 0.84 | CYP3A4 (0.67) | GLSCA1CYP3A4 | |
| SCHEMBL16181822 | 0.84 | GLS (0.55) | GLSKDM4ABRD4CREBBPHDAC1 | |
| SCHEMBL1165088 | 0.84 | GLS (0.55) | GLSKDM4ABRD4CREBBPHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022220725-A1 | LPXH INHIBITORS AS ANTI-INFECTIVE AGENTS | ZAMARATSKI EDOUARD (SE) | 2022-10-20 | — | — | WO | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2019-05-02 | — | — | US | disclosed |
| EP-3452477-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. Pharma (BE) | 2019-03-13 | — | — | EP | disclosed |
| CN-109311882-A | adenine derivatives as protein kinase inhibitors | BCI制药公司 | 2019-02-05 | — | — | CN | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| US-7235562-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2007-06-26 | — | — | US | disclosed |
| CN-1934104-A | Compounds for the treatment of diseases | PFIZER LTD (US) | 2007-03-21 | — | — | CN | disclosed |
| CN-1910143-A | Sulfonamide derivatives for the treatment of diseases | PFIZER LTD (US) | 2007-02-07 | — | — | CN | disclosed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | SMITHKLINE BEECHAM CORPORATION | 2006-09-28 | — | — | US | disclosed |
| EP-1615917-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | Pharmacia & Upjohn Company LLC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040204463-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | HARRIS CHRISTINA RENEE (US) | 2004-10-14 | — | — | US | disclosed |
| WO-2004087697-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20030013883-A1 | Tropane analogs binding to monoamine transporters | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | GLS 1867/4885KDM4A 1661/4885BRD4 1322/4885 |
| US-20190127379-A1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ADK, TNNI3K, TNK2 | GLS 1867/4885KDM4A 1661/4885BRD4 1322/4885 |
| US-20030013883-A1 | Tropane analogs binding to monoamine transporters | SLC6A3, SLC6A2, SLC6A4 | GLS 1935/4885KDM4A 3803/4885BRD4 3731/4885 |
| US-20250313574-A1 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | NEU1, NEU2, NEU4 | GLS 1658/4885KDM4A 4358/4885BRD4 4391/4885 |
| US-20060217382-A1 | 7-(2-Bromophenyl)-5-methyl-N-(3,4,5-trimethoxyphenyl)imidazo[5,1-f][1,2,4]triazin-2-amine; to treat neoplasms; polo like kinases inhibitors; antineoplastic/antiproliferative agents; cyclization of 1,2,4-triazine derivatives; coupling if imidazo[5,1-f][1,2,4]triazines with amine or halogen derivatives | PLK2, PLK1, CDKL5 | GLS 2427/4885KDM4A 997/4885BRD4 242/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | GLS 909/4885KDM4A 2761/4885BRD4 4141/4885 |
| US-20040204463-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | GLS 745/4885KDM4A 1898/4885BRD4 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.